Immune system modulation via allergen-specific T cell response induction

The induction of allergen-specific T cell responses is central to immunotherapeutic approaches for allergic diseases. Rather than targeting a single molecule or receptor, these strategies modulate the immune system by directing allergen-specific T cells toward a regulatory, tolerant phenotype—most notably by increasing regulatory T cell (Treg) activity and reducing type 2 helper T cell (Th2) responses. Key surface molecules involved include **CTLA-4**, **PD-1**, **BTLA**, and **LAG-3**, which function as immune checkpoints to inhibit pathogenic allergen-specific T cell proliferation and cytokine release[1][2][3][4][5]. Allergen-specific immunotherapy (SIT) utilizes modified allergens, peptides, and adjuvants to tip the balance from allergy-promoting Th2 cells toward tolerance-inducing Treg cells, regulating cytokine production (IL-10, TGF-beta) and suppressing harmful immune activation. Tolerance can sometimes be broken by infections or inflammatory signals, which may trigger allergic episodes even in previously tolerant individuals[4]. This process involves multiple molecular families—including T cell receptors (TCRs), various immune checkpoints, secreted cytokines, and cell surface molecules—rather than a single molecular entity. In summary, "Immune system modulation via allergen-specific T cell response induction" is a biological process and therapeutic mechanism, not a unique, defined molecular target or receptor. Further refinement is needed to map this to a specific molecule or receptor suitable for structured data extraction.

Other names

Allergen-specific T cell modulationAllergen-specific immunotherapy mechanismsInduction of allergen-specific T cell tolerance

Induction of T cell tolerance (upregulation of regulatory T cell subsets, suppression of pro-allergic cytokines IL-4, IL-5, IL-13); Modulation of T cell subtypes (increase Treg, decrease Th2/Th1 effector cells); Cytokine-mediated suppression (increased IL-10, TGF-beta, decreased pro-allergic cytokines); Immune checkpoint signaling (PD-1, CTLA-4, BTLA, LAG-3 roles in limiting allergic T cell responses)